Antihypertensive Efficacy of LCZ696 (Sacubitril/Valsartan) in Hypertension

被引：1
|
作者：
Tocci, Giuliano [1 ,2 ]
机构：
[1] Univ Rome Sapienza, Dept Clin & Mol Med, St Andrea Hosp, Rome, Italy
[2] IRCCS Neuromed, Pozzilli, Italy
来源：
CARDIOLOGY | 2020年 / 145卷 / 09期
关键词：
ANGIOTENSIN-II RECEPTOR; NEPRILYSIN; GUIDELINES; ALISKIREN; INHIBITOR;
D O I：
10.1159/000508345
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：599 / 600
页数：2
相关论文
共 50 条
  • [21] Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor-Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2017, 56 : 1461 - 1478
  • [22] The effect of LCZ696 (sacubitril/valsartan) on amyloid-β concentrations in cerebrospinal fluid in healthy subjects
    Langenickel, Thomas H.
    Tsubouchi, Chiaki
    Ayalasomayajula, Surya
    Pal, Parasar
    Valentin, Marie-Anne
    Hinder, Markus
    Jhee, Stanford
    Gevorkyan, Hakop
    Rajman, Iris
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2016, 81 (05) : 878 - 890
  • [23] Erratum to: Clinical Pharmacokinetics of Sacubitril/Valsartan (LCZ696): A Novel Angiotensin Receptor–Neprilysin Inhibitor
    Surya Ayalasomayajula
    Thomas Langenickel
    Parasar Pal
    Sreedevi Boggarapu
    Gangadhar Sunkara
    Clinical Pharmacokinetics, 2018, 57 : 105 - 123
  • [24] LCZ696 (sacubitril/valsartan) inhibits pulmonary hypertension induced right ventricular remodeling by targeting pyruvate dehydrogenase kinase 4
    Shen, Mengjia
    Zheng, Cankun
    Chen, Lu
    Li, Mingjue
    Huang, Xiaoxia
    He, Mingyuan
    Liu, Chiyu
    Lin, Hairuo
    Liao, Wangjun
    Bin, Jianping
    Cao, Shiping
    Liao, Yulin
    BIOMEDICINE & PHARMACOTHERAPY, 2023, 162
  • [25] EFFICACY AND SAFETY OF SACUBITRIL/VALSARTAN (LCZ696) IN HYPERTENSION CONTROL AND ADVERSE CARDIOVASCULAR EVENT REDUCTION AMONG ASIANS: A SYSTEMATIC REVIEW AND META-ANALYSIS
    Vera Cruz, Patrick
    Ang, Wisdom
    Calatrava, Jose
    JOURNAL OF HYPERTENSION, 2022, 40 (SUPPL) : E228 - E228
  • [26] Effects of Sacubitril/Valsartan (LCZ696) on Natriuresis, Diuresis, Blood Pressures, and NT-proBNP in Salt-Sensitive Hypertension
    Wang, Tzung-Dau
    Tan, Ru-San
    Lee, Hae-Young
    Ihm, Sang-Hyun
    Rhee, Moo-Yong
    Tomlinson, Brian
    Pal, Parasar
    Yang, Fan
    Hirschhorn, Elizabeth
    Prescott, Margaret F.
    Hinder, Markus
    Langenickel, Thomas H.
    HYPERTENSION, 2017, 69 (01) : 32 - 41
  • [27] LCZ696 (sacubitril/valsartan), an angiotensin receptor neprilysin inhibitor (ARNI): clinical development in heart failure
    Martin P Lefkowitz
    BMC Pharmacology and Toxicology, 16 (Suppl 1)
  • [28] Pharmacodynamic and Pharmacokinetic Profiles of Sacubitril/Valsartan (LCZ696) in Patients with Heart Failure and Reduced Ejection Fraction
    Kobalava, Zhanna
    Kotovskaya, Yulia
    Averkov, Oleg
    Pavlikova, Elena
    Moiseev, Valentine
    Albrecht, Diego
    Chandra, Priya
    Ayalasomayajula, Surya
    Prescott, Margaret F.
    Pal, Parasar
    Langenickel, Thomas H.
    Jordaan, Pierre
    Rajman, Iris
    CARDIOVASCULAR THERAPEUTICS, 2016, 34 (04) : 191 - 198
  • [29] Influence of Sacubitril/Valsartan (LCZ696) on 30-Day Readmission After Heart Failure Hospitalization
    Desai, Akshay S.
    Claggett, Brian L.
    Packer, Milton
    Zile, Michael R.
    Rouleau, Jean L.
    Swedberg, Karl
    Shi, Victor
    Lefkowitz, Martin
    Starling, Randall
    Teerlink, John
    McMurray, John J. V.
    Solomon, Scott D.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (03) : 242 - 248
  • [30] In vitro and clinical evaluation of OATP-mediated drug interaction potential of sacubitril/valsartan (LCZ696)
    Ayalasomayajula, S.
    Han, Y.
    Langenickel, T.
    Malcolm, K.
    Zhou, W.
    Hanna, I.
    Alexander, N.
    Natrillo, A.
    Goswami, B.
    Hinder, M.
    Sunkara, G.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2016, 41 (04) : 424 - 431
12345